Abstract
Cystatin C (CysC), a cysteine protease inhibitor, has been widely proven to be a highly sensitive biomarker to predict the kidney function. The similarity of the renal and cerebral small vessels has awakened a surge of studies suggesting that CysC plays a key role in various cerebrovascular disorders. This review focuses on four major mechanisms of CysC in a variety of cerebrovascular diseases. (1) The property of the CysC Leu-68-Gln (L68Q) variant to aggregate and the property of the wild type CysC protein to co-aggregate with Amyloid-β (Aβ); (2) The disruption of equilibrium between CysC and related cysteine proteases; (3) The function of CysC as an inflammatory inducing factor; (4) The ability of CysC to induce autophagy. The combination of these CysC properties provides a well-supported novel biomarker for cerebrovascular diseases.
Keywords: CysC, cerebrovascular diseases, cerebral amyloid angiopathy (CAA), cerebral aneurysms (CAs), subarachnoid hemorrhage (SAH), ischemic stroke, cerebral small vascular diseases (CSVDs), vascular dementia (VD).
Current Neurovascular Research
Title:Cystatin C in Cerebrovascular Disorders
Volume: 14 Issue: 4
Author(s): Yaru Zhang and Li Sun*
Affiliation:
- Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun,China
Keywords: CysC, cerebrovascular diseases, cerebral amyloid angiopathy (CAA), cerebral aneurysms (CAs), subarachnoid hemorrhage (SAH), ischemic stroke, cerebral small vascular diseases (CSVDs), vascular dementia (VD).
Abstract: Cystatin C (CysC), a cysteine protease inhibitor, has been widely proven to be a highly sensitive biomarker to predict the kidney function. The similarity of the renal and cerebral small vessels has awakened a surge of studies suggesting that CysC plays a key role in various cerebrovascular disorders. This review focuses on four major mechanisms of CysC in a variety of cerebrovascular diseases. (1) The property of the CysC Leu-68-Gln (L68Q) variant to aggregate and the property of the wild type CysC protein to co-aggregate with Amyloid-β (Aβ); (2) The disruption of equilibrium between CysC and related cysteine proteases; (3) The function of CysC as an inflammatory inducing factor; (4) The ability of CysC to induce autophagy. The combination of these CysC properties provides a well-supported novel biomarker for cerebrovascular diseases.
Export Options
About this article
Cite this article as:
Zhang Yaru and Sun Li *, Cystatin C in Cerebrovascular Disorders, Current Neurovascular Research 2017; 14 (4) . https://dx.doi.org/10.2174/1567202614666171116102504
DOI https://dx.doi.org/10.2174/1567202614666171116102504 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Conference Report: 12<sup>th</sup> International Congress on Neuroprotective Agents (ICNA), Charlottesville, VA, USA September 28, 2014-Ocobert 01, 2014
CNS & Neurological Disorders - Drug Targets Re-Balancing of Inflammation and Aβ Immunity as a Therapeutic for Alzheimers Disease-View from the Bedside
CNS & Neurological Disorders - Drug Targets Nanoparticles as Alternative Strategies for Drug Delivery to the Alzheimer Brain: Electron Microscopy Ultrastructural Analysis
CNS & Neurological Disorders - Drug Targets Calcitonin Gene-Related Family Peptides in Vascular Adaptations, Uteroplacental Circulation, and Fetal Growth
Current Vascular Pharmacology Neurobiology of Alzheimer’s Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions
Current Alzheimer Research Pharmacology of the Intracellular Pathways Activated by Amyloid Beta Protein
Mini-Reviews in Medicinal Chemistry COVID19 - Far from Over: Call for Urgent Novel and Advanced Measures
Coronaviruses Editorial (Thematic Issue: The Link between Alzheimer’s Disease and Down Syndrome. A Historical Perspective)
Current Alzheimer Research Trajectories of Age-Related Cognitive Decline and Potential Associated Factors of Cognitive Function in Senior Citizens of Beijing
Current Alzheimer Research Ocular Biomarkers of Alzheimer’s Disease
Central Nervous System Agents in Medicinal Chemistry Arterial Spin Labeling Perfusion MRI in Alzheimers Disease
Current Medical Imaging PUFA Supplements and Type 2 Diabetes in the Elderly
Current Pharmaceutical Design Statin Treatment Non-adherence and Discontinuation: Clinical Implications and Potential Solutions
Current Pharmaceutical Design Endothelial Dysfunction in the Hypertensive State: Mechanisms of Hypertensive Cardiovascular Complications
Current Hypertension Reviews Recent Advances in the Imaging of Programmed Cell Death
Current Pharmaceutical Design Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability
Current Neuropharmacology Asymmetric Dimethyl-L-Arginine (ADMA): A Possible Link Between Homocyst(e)ine and Endothelial Dysfunction
Current Drug Metabolism An Overview of Notch Signaling in Adult Tissue Renewal and Maintenance
Current Alzheimer Research The Need for Diagnostic Criteria in Systemic Vasculitis
Current Immunology Reviews (Discontinued) Novelty in Inflammation and Immunomodulation in Migraine
Current Pharmaceutical Design